Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-allergic Asthma Clear all

Conditions: Asthma
Interventions: omalizumab, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild or Moderate Asthma With Allergic Sensitization
Interventions: 5-Hydroxytryptophan, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Asthma
Interventions: Omalizumab; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Asthma, Allergic Asthma, Non-allergic Asthma
Interventions: Levocetirizine 0.5 Mg/mL Oral Solution; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 7 Years to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: CJM112, Placebo to CJM112; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Fullerton, California • Riverside, California • Denver, Colorado + 5 more

Conditions: Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Asthma, Allergic Asthma, Non-allergic Asthma
Interventions: Nutritional approach for asthma, Low Caloric Shake, whole lung allergen challenge; Dietary Supplement · Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Disease
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Omaha, Nebraska • Albany, New York

Conditions: Asthma
Interventions: Xolair; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Asthma, Allergic, Asthma, Obesity
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Moderate to Severe Allergic Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more

Conditions: Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions: GDC-6599, GDC-6599-matching placebo, Mannitol; Drug · Other · Diagnostic Test
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more

Conditions: Asthma, Allergies
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mild, Allergic Asthma
Interventions: Gamma Tocopherol 700 mg capsules,, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Effect of Anti-IgE in Non-Allergic Asthma

5HTP Regulation Of Asthma In Children

Soluble CD23 Expression in Asthma Patients Treated With OMA

Characterization of the Role of Histamine in Children With Asthma

Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Asthma Inflammation Research

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Immune Dysfunction in Allergic Asthma

IL13 Signaling in Allergic Asthma

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS